JPRN-jRCT1080222997未知4 期
A Multi-center, Open-label Study of Subcutaneous Secukinumab to Evaluate Efficacy and Safety for 16 Weeks in Patients With Plaque Psoriasis Who Had Inadequate Response to Cyclosporine A
ovartis Pharma K.K.0 个研究点开始时间: 2015年10月27日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Plaque psoriasis diagnosed for at least 6 months before baseline
- •-Treated with cyclosporine A for at least 12 weeks prior to baseline
- •-Currently treated with cyclosporine A at baseline for psoriasis but is a primary or secondary inadequate response as defined at baseline by:
- •-PASI score of 10 or greater and
- •-IGA mod 2011 score of 2 or greater (based on a scale of 0 to 4)
排除标准
- •-Forms of psoriasis other than plaque (e.g., pustular, erythrodermic and guttate psoriasis).
- •-Drug-induced psoriasis (i.e., new onset or current exacerbation from beta-blockers, calcium channel blockers or lithium).
- •-Patients who have to discontinue cyclosporine A treatment due to side effects like renal impairment (serum creatinine exceeding 176.8 micromol/L [2.0 mg/dL]) and hypertension at screening.
- •Other protocol defined inclusion/exclusion criteria may apply.
研究者
相似试验
未知
3 期
Study to assess the efficacy, safety and tolerability of secukinumab in Japanese subjects with GPPGeneralized Pustular Psoriasis (GPP)JPRN-jRCT2080222256ovartis Pharma K.K.
进行中（未招募）
不适用
An Open-label, Randomized Study of Subcutaneous and Intravenous VELCADE® in Subjects With Previously Treated Multiple MyelomaEUCTR2008-000952-28-GBJanssen-Cilag International NV (JCI)216
进行中（未招募）
1 期
An Open-label, Randomized Study of Subcutaneous and Intravenous VELCADE® in Subjects With Previously Treated Multiple MyelomaThe subject population comprises adult male and female subjects with multiple myeloma that has relapsed or progressed after prior systemic antineoplastic therapy, presence of measurable secretory disease, Karnofsky performance status score greater than or equal to 70%, and clinical hematology and chemistry laboratory values that meet predefined criteria.MedDRA version: 9.1Level: LLTClassification code 10028228Term: Multiple myelomaEUCTR2008-000952-28-FRJanssen-Cilag International NV (JCI)
进行中（未招募）
不适用
An Open-label, Randomized Study of Subcutaneous and Intravenous VELCADE® in Subjects With Previously Treated Multiple MyelomaThe subject population comprises adult male and female subjects with multiple myeloma that has relapsed or progressed after prior systemic antineoplastic therapy, presence of measurable secretory disease, Karnofsky performance status score greater than or equal to 70%, and clinical hematology and chemistry laboratory values that meet predefined criteriaMedDRA version: 9.1Level: LLTClassification code 10028228Term: Multiple myelomaEUCTR2008-000952-28-BEJanssen-Cilag International NV (JCI)216
尚未招募
3 期
An Open-label, Randomized Study of Subcutaneous and Intravenous VELCADE in Subjects With Previously Treated Multiple MyelomaNL-OMON32310Janssen-Cilag10